MX364623B - Fragmentos mutantes de ospa y métodos y usos relacionados con estos. - Google Patents

Fragmentos mutantes de ospa y métodos y usos relacionados con estos.

Info

Publication number
MX364623B
MX364623B MX2015000013A MX2015000013A MX364623B MX 364623 B MX364623 B MX 364623B MX 2015000013 A MX2015000013 A MX 2015000013A MX 2015000013 A MX2015000013 A MX 2015000013A MX 364623 B MX364623 B MX 364623B
Authority
MX
Mexico
Prior art keywords
ospa
methods
mutant fragments
uses relating
polypeptide
Prior art date
Application number
MX2015000013A
Other languages
English (en)
Other versions
MX2015000013A (es
Inventor
Comstedt Pär
Lundberg Urban
Meinke Andreas
Hanner Markus
Schüler Wolfgang
Wizel Benjamin
Schlegl Robert
Grohmann Brigitte
Reinisch Christoph
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of MX2015000013A publication Critical patent/MX2015000013A/es
Publication of MX364623B publication Critical patent/MX364623B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un polipéptido que comprende el polipéptido con la secuencia de aminoácidos de la SEQ ID NO: 186; o cualquier variante funcional de dicha secuencia de aminoácidos, con una identidad de secuencia de al menos 80%, más preferentemente al menos 85%, incluso más preferentemente al menos 90%, más preferentemente al menos 95% con la secuencia de SEQ ID NO: 189 y con una diferencia en la capacidad de protección (?pc) entre la variante funcional y el control placebo (negativo) de al menos de 50%, especialmente al menos 60%, preferentemente al menos 70%, más preferentemente al menos 90%, más preferentemente al menos 95%, incluso más preferentemente 95%, .
MX2015000013A 2012-07-06 2013-07-08 Fragmentos mutantes de ospa y métodos y usos relacionados con estos. MX364623B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668627P 2012-07-06 2012-07-06
US13/802,991 US8986704B2 (en) 2012-07-06 2013-03-14 Mutant fragments of OspA and methods and uses relating thereto
PCT/EP2013/064403 WO2014006226A1 (en) 2012-07-06 2013-07-08 MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO

Publications (2)

Publication Number Publication Date
MX2015000013A MX2015000013A (es) 2015-06-04
MX364623B true MX364623B (es) 2019-05-03

Family

ID=49878705

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014949A MX391136B (es) 2012-07-06 2013-07-08 FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
MX2015000013A MX364623B (es) 2012-07-06 2013-07-08 Fragmentos mutantes de ospa y métodos y usos relacionados con estos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018014949A MX391136B (es) 2012-07-06 2013-07-08 FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO

Country Status (24)

Country Link
US (9) US8986704B2 (es)
EP (3) EP3689372A1 (es)
JP (1) JP6276258B2 (es)
KR (2) KR102190981B1 (es)
CN (2) CN104487084B (es)
AU (2) AU2013285364B2 (es)
CA (1) CA2876541C (es)
CY (1) CY1120772T1 (es)
DK (1) DK2869839T3 (es)
EA (2) EA033007B1 (es)
ES (2) ES2688883T3 (es)
HR (1) HRP20181689T1 (es)
HU (1) HUE041286T2 (es)
LT (1) LT2869839T (es)
MX (2) MX391136B (es)
NZ (2) NZ733026A (es)
PL (1) PL2869839T3 (es)
PT (1) PT2869839T (es)
RS (1) RS57847B1 (es)
SI (1) SI2869839T1 (es)
SM (1) SMT201800557T1 (es)
TR (1) TR201815419T4 (es)
WO (1) WO2014006226A1 (es)
ZA (1) ZA201409222B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) * 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
AU2015281021B9 (en) * 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2016022958A2 (en) * 2014-08-07 2016-02-11 The Trustees Of Columbia University In The City Of New York Tick-associated virus sequences and uses thereof
EP3393481A1 (en) * 2015-12-23 2018-10-31 Novartis Ag Oil-in-water emulsions including retinoic acid
WO2017139715A1 (en) * 2016-02-11 2017-08-17 The Translational Genomics Research Institute Systems and methods for the detection of infectious diseases
ES2957939T3 (es) 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
KR20190001421U (ko) 2019-05-26 2019-06-13 이준형 노크형 내부 수납식 칫솔
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111269919B (zh) * 2020-03-19 2021-07-13 四川农业大学 玉米基因ZmLIP2及其应用
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
PT1311540E (pt) * 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
HUE036180T2 (hu) * 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
TWI376385B (en) 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
JP2013503198A (ja) 2009-08-27 2013-01-31 シナプティック リサーチ，リミテッド ライアビリティ カンパニー 人工多能性幹（ｉＰＳ）細胞または組織特異的細胞を誘導するための新規タンパク質送達系
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US9925257B2 (en) 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
JP6304888B2 (ja) 2011-12-06 2018-04-04 ムベア カルボ テック ゲーエムベーハーＭｕｂｅａ Ｃａｒｂｏ Ｔｅｃｈ Ｇｍｂｈ 繊維強化材料製ホイールおよび対応するホイールの作製方法
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
MX369195B (es) 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA3008042A1 (en) 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
ES2957939T3 (es) 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
CN115698044A (zh) 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物

Also Published As

Publication number Publication date
CN107602676B (zh) 2021-06-04
EA201590162A1 (ru) 2015-06-30
CY1120772T1 (el) 2019-12-11
PL2869839T3 (pl) 2018-12-31
US8986704B2 (en) 2015-03-24
ZA201409222B (en) 2016-08-31
US20220185851A1 (en) 2022-06-16
TR201815419T4 (tr) 2018-11-21
HK1207982A1 (en) 2016-02-19
EP2869839A1 (en) 2015-05-13
US20170107263A1 (en) 2017-04-20
NZ703597A (en) 2017-06-30
EA033007B1 (ru) 2019-08-30
AU2017218974A1 (en) 2017-09-07
KR20150036191A (ko) 2015-04-07
EP3360568B1 (en) 2020-03-04
KR20200141096A (ko) 2020-12-17
HK1257893A1 (en) 2019-11-01
US20170101446A1 (en) 2017-04-13
LT2869839T (lt) 2018-11-12
RS57847B1 (sr) 2018-12-31
SMT201800557T1 (it) 2018-11-09
US20140010835A1 (en) 2014-01-09
EP3689372A1 (en) 2020-08-05
HK1248244A1 (zh) 2018-10-12
KR102393038B1 (ko) 2022-04-29
AU2013285364B2 (en) 2017-06-15
US11466058B2 (en) 2022-10-11
US11208439B2 (en) 2021-12-28
CA2876541A1 (en) 2014-01-09
HUE041286T2 (hu) 2019-05-28
JP2015522270A (ja) 2015-08-06
JP6276258B2 (ja) 2018-02-07
US12195501B2 (en) 2025-01-14
CN107602676A (zh) 2018-01-19
MX2015000013A (es) 2015-06-04
NZ733026A (en) 2019-09-27
US9926343B2 (en) 2018-03-27
US20150250865A1 (en) 2015-09-10
CN104487084B (zh) 2017-09-22
HK1209370A1 (en) 2016-04-01
US20180327460A1 (en) 2018-11-15
AU2017218974C1 (en) 2020-02-20
US20230295245A1 (en) 2023-09-21
SI2869839T1 (sl) 2018-11-30
CA2876541C (en) 2022-03-01
ES2800873T3 (es) 2021-01-04
ES2688883T3 (es) 2018-11-07
WO2014006226A1 (en) 2014-01-09
EP2869839B1 (en) 2018-09-05
AU2017218974B2 (en) 2019-05-30
PT2869839T (pt) 2018-11-12
US10544194B2 (en) 2020-01-28
EA201991059A1 (ru) 2020-01-31
MX391136B (es) 2025-03-21
HRP20181689T1 (hr) 2018-12-28
DK2869839T3 (en) 2018-10-15
KR102190981B1 (ko) 2020-12-15
US20200239525A1 (en) 2020-07-30
EP3360568A1 (en) 2018-08-15
CN104487084A (zh) 2015-04-01
US20150232517A1 (en) 2015-08-20
AU2013285364A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
SG10201907775QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
SG10201907522QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
NZ705370A (en) Fcγriib-specific fc region variant
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
MY167232A (en) Polypeptides binding to human complement c5
AU2011328009A8 (en) Compounds and methods for treating pain
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
IN2014DN06920A (es)
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
MX357071B (es) Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
WO2013158818A3 (en) Vaccines and methods to treat lyme disease in dogs
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
GB201114923D0 (en) Immunogenic proteins and compositions
UA99801C2 (ru) Белковая конструкция, которая включает модифицированный полипептид casb7439

Legal Events

Date Code Title Description
FG Grant or registration